Abstract Library

#2299 Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,

Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,

#2180 BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model

Introduction: NECs of colon origin are orphan and highly aggressive neoplasms with limited molecular knowledge.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Capdevila J

Authors: Capdevila J, Mancuso F, Landolfi S, Martinez-Cardus A, Barriuso J,

Keywords: Neuroendocrine carcinoma, Genomics, Epigenomics, BRAFV600E, Patient-derived xenograft,

#2087 Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Capdevila J

Authors: Capdevila J, Hernando J, Casanovas O, Lachamp L, Cabello F,

Keywords: Somatostatin analogues, New release mechanism, High doses,

#1532 Epidemiology, Pathological Features and Clinical Outcome of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)

Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs coordinated by the scientific multidisciplinary Spanish society GETNE, that covers 57 academic and community sites representing all regions of Spain.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Jimenez-Fonseca P, Capdevila J, Alonso Orduña V, Fernández Medina I, Teule Vega A,

Keywords: Neuroendocrine tumor, registry, Spain, survival,

#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms

Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,

Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,